Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

Inclusion Criteria: * Histologically confirmed cervical intraepithelial neoplasia 1 (CIN 1) AND oncogenic human papillomavirus (HPV) positivity * At increased risk for developing cervical cancer due to \>= 1 of the following criteria (documented 6-12 months ago)\*: * Positive oncogenic HPV on DNA hybrid capture * Low-grade squamous intraepithelial lesion cytology * Histopathologically documented CIN 1 on cervical biopsy \[Note: \*Patients must now have current CIN 1 by histology or colposcopy AND HPV positivity\] * Cervical dysplasia by colposcopy OR positive biopsy * No invasive cervical cancer or high-grade intraepithelial neoplasia on cervical biopsy or endocervical curettage * ECOG performance status \< 2 * Total bilirubin \< 2 times upper limit of normal (ULN) * AST \< 2 times ULN * ALT normal * Creatinine \< 2.0 mg/dL * Able and willing to return to clinic for study visits once every 4 weeks for the duration of the study * No history of allergic reaction to tea or related dietary products * No HIV positive patients (or AIDS/HIV-associated complex) * No uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection other than HPV * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situation that would limit compliance with study requirements * No history of any cancer except nonmelanoma skin cancer * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No regular intake of 6 or more servings of tea per week within 1 month prior to study entry * No treatment for genital condyloma within 30 days prior to study entry * No prior pelvic irradiation * No concurrent tea (green, black, or oolong) or tea-derived products * No other concurrent investigational agents